Section Arrow
ROIV.NASDAQ
- Roivant Sciences Ltd
Quotes are at least 15-min delayed:2025/09/04 04:01 EDT
Pre Market
Last
 --
-- (--)
Bid
12.2
Ask
12.75
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 12.59
+0.2 (+1.61%)
Day High 
12.745 
Prev. Close
12.39 
1-M High
12.465 
Volume 
10.39M 
Bid
12.2
Ask
12.75
Day Low
12.28 
Open
12.38 
1-M Low
10.9 
Market Cap 
8.46B 
Currency USD 
P/E 1.95 
%Yield -- 
10-SMA 11.89 
20-SMA 11.77 
50-SMA 11.52 
52-W High 13.055 
52-W Low 8.73 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.70/-1.40
Enterprise Value
8.55B
Balance Sheet
Book Value Per Share
6.36
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
29.05M
Operating Revenue Per Share
0.12
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PMNProMIS Neurosciences0.4574-0.0792-14.76%6.98PE
Pre Market -- -- --
ADAPAdaptimmune Therapeutics plc0.0526-0.0052-9.00%-- 
Pre Market 0.0572 +0.0046 +8.75%
CARMCarisma Therapeutics0.3699-0.0701-15.93%-- 
Pre Market 0.3497 -0.0202 -5.46%
ETHZETHZilla Corporation2.52-0.15-5.62%-- 
Pre Market 2.48 -0.04 -1.59%
STTKShattuck Labs1.28+0.27+26.73%-- 
Pre Market 1.25 -0.03 -2.34%
Quotes are at least 15-min delayed:2025/09/04 04:01 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.